Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
about
Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?Improved nutritional status is related to improved quality of life in Parkinson's disease.Effect of zishenpingchan granule on neurobehavioral manifestations and the activity and gene expression of striatal dopamine d1 and d2 receptors of rats with levodopa-induced dyskinesias.Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia.Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's diseasePatient perspectives on Parkinson's disease therapy in Japan and the United States: results of two patient surveys.Markers of disease severity are associated with malnutrition in Parkinson's disease.Anti-apoptotic effect of Shudipingchan granule in the substantia nigra of rat models of Parkinson's disease.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden: an exploratory study.Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.L-Dopa and Brain Serotonin System Dysfunction.Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study.Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity.
P2860
Q26768220-6AEE78C1-71C2-4945-8052-6C185317C8FCQ34544024-08911925-0B05-445F-B976-ACC7ADCA1D69Q34588665-DAED679A-B123-4E87-8D8E-9F77C0EE89E0Q34853030-275E370C-8CFC-4271-97B4-D6D1DA89BC82Q35324977-754F468D-9CC0-4926-B679-41F5C11DE9ADQ35605023-F2468544-6AA9-4653-89CB-2FB0D88E4858Q36429865-BE3EDE2B-2E8C-4BC4-A059-A216F741B19EQ36721175-A8BFD9FC-4568-440C-93CC-F63CFF0AA9C3Q37425231-1B2F8DA0-7AD3-470F-BB45-BE3B1CCBA637Q38811387-D92CAE40-9485-45B8-8830-52FDD6A125C4Q39942155-EDBC27C2-0B74-4400-9D37-0EBCE2CF9DDEQ42705333-698094C3-C380-44A3-805A-3319E72B5225Q43121312-2296A9A3-60BD-49AD-89A4-CE0D334A32FBQ44925523-DE347B1A-CAAC-4FAA-884A-6B9640AB010EQ47112234-81780AED-4FF2-49C6-B797-42F2949EA98BQ48050563-DEA8008D-217D-4E0F-B2AA-747E306F57FEQ55118987-41CA5C05-EBA8-40A6-9DF2-7BD7119403D6
P2860
Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Levodopa-induced dyskinesias i ...... ality of life, and treatments.
@en
Levodopa-induced dyskinesias i ...... ality of life, and treatments.
@nl
type
label
Levodopa-induced dyskinesias i ...... ality of life, and treatments.
@en
Levodopa-induced dyskinesias i ...... ality of life, and treatments.
@nl
prefLabel
Levodopa-induced dyskinesias i ...... ality of life, and treatments.
@en
Levodopa-induced dyskinesias i ...... ality of life, and treatments.
@nl
P921
P356
P1433
P1476
Levodopa-induced dyskinesias i ...... ality of life, and treatments.
@en
P2093
Elmyra V Encarnacion
P356
10.1159/000131893
P577
2008-05-15T00:00:00Z